Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Stock Information for Oramed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
Lifeward Successfully Closes on Strategic Partnership with Oramed
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed-Creating Diversified Biomedical Company
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Oramed and Lifeward Announce Strategic Transaction
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Oramed Reports Fiscal Third Quarter 2025 Financial Results
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.